Wedbush initiates coverage on Cartesian Therapeutics stock with Outperform rating

Wedbush initiated coverage on Cartesian Therapeutics (NASDAQ: RNAC) with an Outperform rating and a $38 price target, citing the clinical-stage biopharmaceutical company's mRNA cell therapies for immunology and inflammation. The firm highlighted significant advantages of RNAC's therapies over standard DNA-based CAR-T cell therapies, including improved safety and redosing potential. Wedbush specifically noted the lead candidate Descartes-08's promising Phase 2 results in myasthenia gravis, with its registrational Phase 3 AURORA trial now actively enrolling, contributing to a broader analyst consensus of a strong buy.

Analysis

Cartesian Therapeutics (RNAC) has received a significant vote of confidence with Wedbush initiating coverage at an 'Outperform' rating and a $38 price target, reinforcing a strong buy consensus among analysts. The bullish thesis is anchored in the company's proprietary mRNA cell therapy platform, which offers notable advantages over traditional DNA-based CAR-T therapies, including improved safety, redosing potential, and lower cost of goods sold without the need for lymphodepletion. The lead candidate, Descartes-08, is a key value driver, having demonstrated deeper responses in its Phase 2 myasthenia gravis trial compared to approved biologics. A critical milestone has been achieved with the enrollment of the first patient in the registrational Phase 3 AURORA trial for this indication, moving the asset closer to potential approval. Further upside is presented by pipeline expansion into other autoimmune diseases, such as a Phase 2 lupus trial with initial data anticipated in the second half of 2025. This positive outlook is echoed by analysts at H.C. Wainwright and BTIG, who maintain Buy ratings with price targets of $40 and $42, respectively. While the company recently announced the transition of its Chief Technology Officer to a consulting role, the overall operational and clinical momentum appears strong.

Key Decisions for Investors

• Given the strong analyst consensus and the initiation of a pivotal Phase 3 trial for its lead candidate, investors with a high risk tolerance may consider the stock a compelling long-term holding in the advanced therapy space.
• Key catalysts to monitor are the enrollment progress and eventual data from the Phase 3 AURORA trial, as well as the initial data readout from the Phase 2 lupus trial expected in H2 2025.
• Investors should weigh the significant potential of the mRNA platform against the inherent clinical and regulatory risks of a development-stage biotech company before establishing or increasing a position.